Motley Fool Wealth Management LLC Buys Shares of 894,471 Alphatec Holdings, Inc. (NASDAQ:ATEC)

Key Points

• Motley Fool Wealth Management LLC has invested approximately $9.07 million in Alphatec Holdings, acquiring 894,471 shares, which represents 0.61% ownership of the company.
• Alphatec's stock recently reported earnings per share (EPS) of $0.02, surpassing analysts' expectations and showing a year-over-year revenue increase of 27.5%.
• A number of analysts have upgraded their ratings on Alphatec shares, with Barclays setting a new price target of $22.00, reflecting growing confidence in the company's performance.

Motley Fool Wealth Management LLC purchased a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 894,471 shares of the medical technology company's stock, valued at approximately $9,070,000. Motley Fool Wealth Management LLC owned about 0.61% of Alphatec at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ATEC. Comerica Bank increased its holdings in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Quarry LP grew its stake in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares in the last quarter. Larson Financial Group LLC acquired a new position in shares of Alphatec during the first quarter worth $54,000. Lazard Asset Management LLC purchased a new stake in Alphatec in the fourth quarter valued at $76,000. Finally, State of Wyoming purchased a new stake in Alphatec in the fourth quarter valued at $86,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Trading Up 0.2%

Alphatec stock traded up $0.04 during midday trading on Friday, reaching $15.61. The stock had a trading volume of 630,362 shares, compared to its average volume of 2,068,553. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $16.01. The stock's 50-day simple moving average is $11.88 and its 200 day simple moving average is $11.40. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. The stock has a market capitalization of $2.31 billion, a PE ratio of -13.82 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The company had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. During the same period last year, the company posted ($0.29) earnings per share. The firm's revenue was up 27.5% compared to the same quarter last year. Analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 target price on shares of Alphatec in a report on Friday, May 2nd. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research note on Monday, June 16th. Barclays restated an "overweight" rating and set a $22.00 target price (up from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Piper Sandler reiterated an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Finally, Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $18.50.

Insider Activity

In related news, EVP Craig E. Hunsaker sold 10,876 shares of Alphatec stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $15.33, for a total transaction of $166,729.08. Following the sale, the executive vice president owned 1,389,142 shares of the company's stock, valued at $21,295,546.86. The trade was a 0.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the business's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total transaction of $269,751.72. Following the completion of the sale, the general counsel directly owned 438,331 shares of the company's stock, valued at $6,535,515.21. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 449,997 shares of company stock worth $5,846,616. Corporate insiders own 20.90% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.